Key Catalysts Make Arcutis a Must Watch!
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company developing novel treatments for dermatological diseases, announced the acceptance of the New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) for the treatment of plaque psoriasis in adults and adolescents, filed by Arcutis Canada Inc., a subsidiary of...
